Menu
Not yet recruiting NCT07307040

Precision Diabetes Management: Integrated East-West Approach

— Observational Early-Onset Type 2 Diabetes

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: No interventions.
Who it may be relevant to
Registry conditions: Early-Onset Type 2 Diabetes. Basic parameters: 18 years — 40 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Construction of a Precision and Individualized Management Model for Diabetes With Integrated Traditional Chinese and Western Medicine

Overview

This project will leverage a large-scale cohort of early-onset type 2 diabetes patients to conduct innovative prospective clinical research. By integrating traditional Chinese medicine diagnostic information, clinical data, laboratory results, continuous glucose monitoring, genetic information, multi-omics data, and multi-modal monitoring data, and utilizing advanced data analysis methods such as deep learning, the project aims to establish a comprehensive monitoring, precise classification, and personalized diagnosis and treatment model-a holistic management approach integrating traditional Chinese and Western medicine for early-onset type 2 diabetes. This initiative is expected to enhance the management of early-onset type 2 diabetes, improve treatment outcomes and quality of life for affected patients, pioneer an innovative path for personalized integrated traditional Chinese and Western medicine management in this population, and promote the application of precision medicine in diabetes prevention and treatment.

Interventions

  • Other No interventions
    No interventions

Primary outcome measures

  • Traditional Chinese Medicine Syndrome Score [Time frame: Through study completion, an average of 3 months]
  • HbA1c [Time frame: Through study completion, an average of 3 months]
Secondary outcome measures (5)
  • Triglycerides [Time frame: Through study completion, an average of 3 months]
  • High-Density Lipoprotein Cholesterol [Time frame: Through study completion, an average of 3 months]
  • Total Cholesterol [Time frame: Through study completion, an average of 3 months]
  • Fasting Blood Glucose [Time frame: Through study completion, an average of 3 months]
  • Low-Density Lipoprotein Cholesterol [Time frame: Through study completion, an average of 3 months]

Eligibility criteria

Inclusion criteria

  • The age at diabetes diagnosis is ≥18 years but <40 years.

Exclusion criteria

  • The clinical diagnosis was type 1 diabetes, and at the time of enrollment, antibody levels or insulin/C-peptide results still supported the original diagnosis.

There were clear secondary factors contributing to hyperglycemia, such as Cushing's syndrome or pheochromocytoma.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07307040 · CXZH2024059

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗